DOCSLIB.ORG

Hemoglobins, Hemorphins, and 11P15.5 Chromosomal Region in Cancer Biology and İmmunity with Special Emphasis for Brain Tumors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hemoglobins, Hemorphins, and 11P15.5 Chromosomal Region in Cancer Biology and İmmunity with Special Emphasis for Brain Tumors Review Article 247 Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and İmmunity with Special Emphasis for Brain Tumors Meric Adil Altinoz1 Ilhan Elmaci2 Bahri Ince3 Aysel Ozpinar4 Aydin Murat Sav5 1 Department of Immunology, Istanbul University, DETAE - Address for correspondence Meric Adil Altinoz, MD, Department of Experimental Medicine Research Institute, Istanbul, Turkey Immunology, Istanbul University, DETAE - Experimental Medicine 2 Department of Neurosurgery, Memorial Hospital, Istanbul, Turkey Research Institute, Istanbul, Turkey 34300 3 Department of Psychiatry, Bakirkoy Mental Diseases Education and (e-mail: [email protected]). Training Hospital, Istanbul, Turkey 4 Department of Biochemistry, Acibadem University, Istanbul, Turkey 5 Department of Pathology, Acibadem University, Istanbul, Turkey J Neurol Surg A 2016;77:247–257. Abstract In systemic cancers, increased hemolysis leads to extracellular hemoglobin (HB), and experimental studies have shown its provoking role on tumor growth and metastasis. However, investigations have shown that HB chains presented by tumor vascular pericytes or serum protein complexes of HB could also induce antitumor immunity, which may be harnessed to treat refractory cancers and brain tumors. Mounting recent evidence shows that expression of HBs is not restricted to erythrocytes and that HBs exist in the cells of lung and kidney, in macrophages, and in neurons and glia of the central nervous system (CNS). HBs mediate coping with hypoxia and free radical stress in normal and tumor cells, and they are increased in certain tumors including breast, lung, colon, and squamous cell cancers. Recent studies showed HBs in meningioma, in the cyst fluid of craniopharyngioma, in the cerebrospinal fluid (CSF) of pediatric patients with posterior fossa tumors, and in glioblastoma cell lines. Hemorphins, abundant brain peptides formed via HB-chain cleavage, exert opioid activity and antiproliferative and immunomodifier effects. Hence mutations in HBs may modify brain tumorigenesis via influencing hemorphins and perturbing regulations of immune surveillance and cell growth in the neuroectodermal tissues. The β-globin gene cluster resides in the chromosome region 11p15.5, harboring important immunity genes and IGF2, H19, PHLDA2/TSSC3, TRIM3, and SLC22A18 genes associated with cancers and gliomas. 11p15.5 is a prominent region subject to epigenetic regulation. Thus the β-globin loci may exert haplotypal interactions with these. Some clues support this theory. It is well established that iron load induces liver cancer in thalassemia major; however iron Keywords load–independent associations also exist. Enhanced rates of hematologic malignancies ► hemoglobins are associated with HB Lepore, association of hemoglobin E with cholangiocarcinoma, ► brain tumors and enhanced gastric cancer rates in the thalassemia trait. In the African Herero ► 11p15.5 gene cluster population, a mutant form of δ-globin is very prevalent, and this population has higher received © 2016 Georg Thieme Verlag KG DOI http://dx.doi.org/ April 30, 2015 Stuttgart · New York 10.1055/s-0035-1566120. accepted after revision ISSN 2193-6315. August 11, 2015 published online March 2, 2016 248 Novel Pathways of Glial Tumor Formation Altinoz et al. rates of pediatric brain tumors. Globins are also expressed in healthy endothelia and in tumoral vessels, indicating potential involvement in angiogenesis. Studies on HBs and their cleavage peptides in cancers and brain tumors may lead to innovative treatment strategies. Introduction Gower-2 (α2ε2), Portland-1 (ζ2γ2) HB, and HB-F (fetal hemo- globin) (α2γ2). In adults, three HBs exist: the major adult HB- Primary central nervous system (CNS) tumors have gained A(α2β2, 97%) and the minor HBs, HB-A2 (α2δ2, < 3%)11 the attention of researchers for many reasons. In high-grade and HB-F (<0.6%).12 HB-A consists of two α- and two β-globin glial tumors, maximum surgical resection, radiotherapy, and globular chain proteins assembling into a α2β2 heterote- adjuvant temozolomide is the new standard of care. Yet the tramer, where each globin molecule binds a heme prosthetic 13 median survival of patients with glioblastoma multiforme group. In adult HB, the carriage of O2 is mediated via (GBM) is 15 months.1 This outcome is alarmingly poor; binding of the ligand to heme iron. Carbon dioxide is trans- hence deciphering novel pathways of glial tumor formation is ported in the blood in solution and by interactions with the essential to develop better treatments. In other brain tumors aminoterminal residues of HB and not via binding to the that are not as invasive as GBM, patients’ morbidity and heme iron.3 HB is also involved in the generation, transport, mortality after surgical resection are still high due to the and scavenging of NO and its metabolic derivatives.3,14,15 The obvious essentiality of all neural tissues in the CNS. In antioxidant functions of intracellular HB and superoxide and systemic cancers, survival ratios are still far from satisfactory hydrogen peroxide scavenger properties were discovered,9,16 for metastatic disease. and its detoxification of oxidizing radicals yields nontoxic In this review, we discuss hemoglobin (HB) chains, hem- ferric states.17 orphins formed via cleavage of globin chains,2 and the 11p15.5 gene locus pertinent to malignancies with special Tumor-Provoking Roles of Extracellular HBs emphasis on brain tumors. The 11p15.5 is a chromosomal 3 site, where β-globin gene cluster and genes in association To expand in size, tumors must recruit new vessels for O2 and with gliomagenesis reside including IGF-2, H19, TSSC3, TRIM3, nutrient supply.18 Elevation of vascular endothelial growth and SLC22A18. Important genes of immunity also reside factor A (VEGF-A)19 and mechanical stress generated by here,4 and loss of heterozygosity (LOH) events at this site expanding tumor cells result in tortuous vessels18 leading are frequent in high-grade glial tumors.5 Because 11p15.5 is a to an uneven blood flow and lower perfusion within prominent chromosomal site subject to epigenetic regulation tumors.20 However, tumors manage to expand despite insuf- such as imprinting, the β-globin gene cluster and glioma- ficient vascular supply, suggesting other mechanisms of O2 susceptibility genes may exert haplotypal associations. In the delivery. Tumor cells are able to form primitive microvessels – last decade, the presence of HB chains in nonerythroid cells via vasculogenic mimicry (VM),21 23 and highly invasive and their upregulation in malignancies were discovered. tumors line fluid-conducting channels.21 However, an effi- Expressions of HB chains in macrophages,6 lung cells,7,8 renal cient RBC circulation through these channels is problematic mesangium,9 and retinal ganglion cells10 were found, and because these channels exert varying diameters22 and are 21 their roles in oxygen (O2) sensing and protection against free often too small (< 5 µm in diameter). Retraction of endo- radicals were discovered. thelial cell (EC)-lined blood vessels leave empty sleeves composed only of basement membrane24 resembling inver- 23 tebrate vessels. In invertebrates, extraerythrocytic HB-O2 A Short Description of HB Genetics and 25 26 Biochemistry exists and transports O2 through the organism. Although fluid-conducting primitive channels and tumoral vasculo- 27 HBs are heme-containing proteins binding O2,carbonmon- genic mimicry may hamper efficient RBC circulation, they oxide, and nitric oxide (NO). In red blood cells (RBCs), HB may facilitate diffusion of free HB. accounts for 98% of proteins, and during differentiation Hence a four-step process is suggested, where extracellular 28 from reticulocytes, RBCs finish the synthesis of HB before HB contributes to tumoral O2 delivery. First, hemolysis in 2 28 ribosomal degradation. The human α-globin gene cluster tumor vessels generates extraerythrocytic HB-O2. Second, locates on chromosomal region 16p13.3 and includes seven extraerythrocytic HB-O2 is transported within the small loci2:5′- zeta(ζ) – pseudozeta (Ψζ) – mu(µ) – pseudoalpha1 intercellular channels in plasma. Third, within the hypoxic (Ψα1) – α2–α1–theta(θ) – 3′.Thehumanβ-globin gene and acidic tumor environment, extraerythrocytic HB-O2 cluster locates on chromosomal region 11p15.5 and includes delivers O2 to adjacent tumor cells. And finally, the deoxy- five loci2:5′–epsilon(ε) – gammaG (Gγ) – gammaA(Aγ) – genated HB close to the EC-lined tumor vessels deprives delta(δ) – β(β) – 3′. During ontogeny, developing erythro- intraerythrocytic HB-O2 of O2, thus starting a new cycle of 28 blasts sequentially express embryonic Gower-1 (ζ2ε2), O2 transport. It was also demonstrated with experimental Journal of Neurological Surgery—Part A Vol. 77 No. A3/2016 Novel Pathways of Glial Tumor Formation Altinoz et al. 249 29 3þ studies that ECs could uptake free HB, yet it remains to be is in the ferric (Fe ) state, it cannot bind O2. In human blood, shown whether this is relevant for tumor vessels. metHB occurs at trace amounts spontaneously (1 to 2% of total Tumor cells enhance procoagulant activity (PCA) and HB) or at higher levels during oxidizing conditions. NO reacts platelet adhesion on their surface shield cancer antigens to with oxyHB to produce metHB, and most of the metHB in facilitate escape from immune surveillance and reduce their RBCs is derived from this oxidation.3 The metHB is also shear stress–associated death in circulation. Tissue factor (TF) present in solid tumors detectable by MR imaging37
Load more

Recommended publications
  • Proquest Dissertations
    Opioid peptide permeation across the blood- brain and blood-cerebrospinal fluid barriers Item Type text; Dissertation-Reproduction (electronic) Authors Abbruscato, Thomas John, 1970- Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 05:24:05 Link to Item http://hdl.handle.net/10150/282429 INFORMATION TO USERS This manuscript has been reproduced from the microfihn master. UMI fihns the text direct^ from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter &ce, while others may be from any type of computer printer. The quality of this reproductioii is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, b^inning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Genscript Product Catalog 2013-2014 Genscript Product Catalog
    GenScript Product Catalog 2013-2014 GenScript Product Catalog www.genscript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854USA Tel: 1-732-885-9188 / 1-732-885-9688 Toll-Free Tel: 1-877-436-7274 Fax: 1-732-210-0262 / 1-732-885-5878 Email: [email protected] Nucleic Acid Purification and Analysis Business Development Tel: 1-732-317-5088 PCR PCR and Cloning Email: [email protected] Protein Analysis Antibodies 2013-2014 Peptides Welcome to GenScript GenScript USA Incorporation, founded in 2002, is a fast-growing biotechnology company and contract research organization (CRO) specialized in custom services and consumable products for academic and pharmaceutical research. Built on our assembly-line mode, one-stop solutions, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of products and services at the most competitive prices in the industry to meet your research needs every day. Over the years, GenScript’s scientists have developed many innovative technologies that allow us to maintain our position at the cutting edge of biological and medical research while offering cost-effective solutions for customers to accelerate their research. Our advanced expertise includes proprietary technology for custom gene synthesis, OptimumGeneTM codon optimization technology, CloneEZ® seamless cloning technology, FlexPeptideTM technology for custom peptide synthesis, BacPowerTM technology for protein expression and purification, T-MaxTM adjuvant and advanced nanotechnology for custom antibody production, as well as our ONE-HOUR WesternTM detection system and eStain® protein staining system. GenScript offers a broad range of reagents, optimized kits, and system solutions to help you unravel the mysteries of biology. We also provide a comprehensive portfolio of customized services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations.
    [Show full text]
  • Entropy-Driven Binding of Opioid Peptides Induces a Large Domain Motion in Human Dipeptidyl Peptidase III
    Entropy-driven binding of opioid peptides induces a large domain motion in human dipeptidyl peptidase III Gustavo A. Bezerraa, Elena Dobrovetskyb, Roland Viertlmayra, Aiping Dongb, Alexandra Binterc, Marija Abramic´d, Peter Macherouxc, Sirano Dhe-Paganonb,e, and Karl Grubera,1 aInstitute of Molecular Biosciences, University of Graz, A-8010 Graz, Austria; eDepartment of Physiology and bStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada M5G 1L7; cInstitute of Biochemistry, Graz University of Technology, A-8010 Graz, Austria; and dDivision of Organic Chemistry and Biochemistry, Ruđer Boskovic Institute, 10002 Zagreb, Croatia Edited by William W. Bachovchin, Tufts University School of Medicine, Boston, MA, and accepted by the Editorial Board March 9, 2012 (received for review November 2, 2011) Opioid peptides are involved in various essential physiological of action compared with morphine, spinorphin is an analgesic, processes, most notably nociception. Dipeptidyl peptidase III (DPP potentially useful for pain treatment in morphine-resistant cases III) is one of the most important enkephalin-degrading enzymes (14). This opioid peptide was also shown to be a potent and se- associated with the mammalian pain modulatory system. Here we lective antagonist of the receptor P2X3, which is involved in pain describe the X-ray structures of human DPP III and its complex with signaling in chronic inflammatory nociception and neuropathic the opioid peptide tynorphin, which rationalize the enzyme’s sub- pain due to nerve injury (15). strate specificity and reveal an exceptionally large domain motion Tynorphin (Val-Val-Tyr-Pro-Trp), a synthetic, truncated form upon ligand binding. Microcalorimetric analyses point at an en- of spinorphin, is a highly specific inhibitor of DPP III and was tropy-dominated process, with the release of water molecules shown to induce an even more potent antinociceptive effect from the binding cleft (“entropy reservoir”) as the major thermo- (14, 16).
    [Show full text]
  • Pharmaceutical Nasal Compositions and Methods for Peptid Treatment
    (19) TZZ ¥Z_T (11) EP 2 283 850 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/485 (2006.01) A61K 9/107 (2006.01) 25.04.2018 Bulletin 2018/17 A61K 9/08 (2006.01) A61K 38/02 (2006.01) A61K 38/25 (2006.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 10186116.9 A61K 31/365 A61K 9/00 A61K 47/32 (2006.01) A61K 47/22 (2006.01) A61K 47/06 (2006.01) A61K 47/08 (2006.01) (22) Date of filing: 07.03.2005 A61K 47/10 (2017.01) A61K 47/18 (2017.01) A61K 47/44 (2017.01) (54) Pharmaceutical nasal compositions and methods for peptid treatment Pharmazeutische nasale Zubereitungen und Peptidbehandlungen Compositions pharmaceutiques nasales et traitements aux peptides (84) Designated Contracting States: • Reppucci, Carl AT BE BG CH CY CZ DE DK EE ES FI FR GB GR North Andover, MA 01845 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR (74) Representative: Chajmowicz, Marion et al (30) Priority: 05.03.2004 US 895465 Becker & Associés 25, rue Louis Le Grand (43) Date of publication of application: 75002 Paris (FR) 16.02.2011 Bulletin 2011/07 (56) References cited: (62) Document number(s) of the earlier application(s) in WO-A-03/000158 accordance with Art. 76 EPC: 05724894.0 / 1 773 369 Remarks: Thefile contains technical information submitted after (73) Proprietor: CPEX Pharmaceuticals, Inc. the application was filed and not included in this Exeter, NH 03833 (US) specification (72) Inventors: • Gyurik, Robert Exeter, NH 03833 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Formylpeptide Receptor N Antagonist at The
    The Endogenous Opioid Spinorphin Blocks fMet-Leu-Phe-Induced Neutrophil Chemotaxis by Acting as a Specific Antagonist at the N-Formylpeptide Receptor This information is current as Subtype FPR of October 1, 2021. Thomas S. Liang, Ji-Liang Gao, Omid Fatemi, Mark Lavigne, Thomas L. Leto and Philip M. Murphy J Immunol 2001; 167:6609-6614; ; doi: 10.4049/jimmunol.167.11.6609 Downloaded from http://www.jimmunol.org/content/167/11/6609 References This article cites 48 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/11/6609.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Endogenous Opioid Spinorphin Blocks fMet-Leu-Phe-Induced Neutrophil Chemotaxis by Acting as a Specific Antagonist at the N-Formylpeptide Receptor Subtype FPR Thomas S.
    [Show full text]
  • Opioids, Neutral Endopeptidase, Its Inhibitors and Cancer: Is There a Relationship Among Them?
    Arch. Immunol. Ther. Exp. DOI 10.1007/s00005-014-0311-0 REVIEW ARTICLE Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them? Magdalena Mizerska-Dudka • Martyna Kandefer-Szerszen´ Received: 11 March 2014 / Accepted: 18 June 2014 Ó The Author(s) 2014. This article is published with open access at Springerlink.com Abstract The role of endogenous animal opioids in the CKI Cyclin dependent inhibitory kinases biology of cancer is widely recognized but poorly under- ECM Extracellular matrix stood. This is, among others, because of the short half-life FAK Focal adhesion kinase of these peptides, which are quickly inactivated by endo- GPI-complex Glycosyl phosphatidyl inositol complex peptidases, e.g., neutral endopeptidase (NEP, CD10). It has MAP kinases Mitogen-activated protein kinases been established that NEP is engaged in the modulation of mRNA Messenger RNA the tumor microenvironment, among others that of colon NEP Neutral endopeptidase cancer, by exerting influence on cell growth factors, the NK Natural killer cells extracellular matrix and other biologically active sub- OGF Opioid growth factor stances. Although there are some discrepancies among the OGFr Opioid growth factor receptor findings on the role of both opioids and NEP in cancer PROL1 Proline rich, lacrimal 1 development, authors agree that their role seems to depend PTEN Phosphatase and tensin homolog deleted on the origin, stage and grade of tumor, and even on the on chromosome Ten method of examination. Moreover, recently, natural SGP-T Submandibular gland peptide-T inhibitors of NEP, such as sialorphin, opiorphin and spin- SMR1 Submandibular rat1 protein orphin have been detected.
    [Show full text]
  • Opiorphin- Inhibitors of Enkephalins by Inactivating Ectopeptidases
    Human Journals Review Article April 2020 Vol.:18, Issue:1 © All rights are reserved by GAURAV M. PRAJAPATI Opiorphin- Inhibitors of Enkephalins by Inactivating Ectopeptidases Keywords: Injury, opiorphin, enkephalins, growth, glutamine, NEP & AP-N Sensitive, bioavailability ABSTRACT GAURAV M. PRAJAPATI*1 The unpleasant physical sensation caused by illness or injury is *1Department of pharmacology, Kasturi Shikshan called pain and substances which are used in reducing or giving Sanstha’s college of Pharmacy, Pune-412208, relief in pain are called analgesics. Human saliva is a natural pain Maharashtra, India killer which is six times more potent than morphine and consists of enkephalins inhibiting enzymes in human neutral ecto Submission: 24 March 2020 endopeptidase and ectoamino peptidase. Without directly Accepted: 31 March 2020 interacting with an opioid receptor opiorphin extracts with Published: 30 April 2020 antinociceptive effect by activating of mu and delta receptor. Opiorphin and its derivatives treated with the disorder that included pain and mood-related disorder. Gene coding opiorphin can be the biomarker of erectile dysfunction. Glutamine is the first position that is crucial for its pharmacological actions on gastrointestinal motility. Opiorphin play physiological roles in www.ijppr.humanjournals.com follicular growth, ovulation, and embryo implantation processes including maternal-fetal including control of the local concentration of NEP & AP- NSensitive. It also helps in the modulation of lachrymal homeostatic by increasing the bioavailability of enkephalins. www.ijppr.humanjournals.com INTRODUCTION Pain is defined as an unpleasant emotional and sensory experience associated with actual and potential tissue damage1. Pain is rarely of two types chronic and acute that differs from each other based on etiology and pathophysiology.
    [Show full text]
  • 2009-2010 Catalogue Peptide
    2009­2010 Peptide Catalogue Generic Peptides Cosmetic Peptides Catalogue Peptides Designer BioScience Ltd Designer BioScience Table of Contents Ordering Information........................................................................................................................................2 Terms and Conditions.......................................................................................................................................3 Generic Peptides...............................................................................................................................................5 Cosmetic peptides...........................................................................................................................................10 Catalogue Peptides..........................................................................................................................................11 Custom Peptide Synthesis.............................................................................................................................292 Alphabetical Index........................................................................................................................................294 Catalogue Number Index..............................................................................................................................319 Designer BioScience Ltd, St John's Innovation Centre, Cambridge, CB4 0WS, United Kingdom Tel.: +44 (0) 1223 322931 Fax: +44 (0) 808 2801 506 [email protected]
    [Show full text]
  • Certificate of Analysis
    Print Date: Nov 13th 2018 Certificate of Analysis www.tocris.com Product Name: Spinorphin Catalog No.: 2931 Batch No.: 1 CAS Number: 137201-62-8 1. PHYSICAL AND CHEMICAL PROPERTIES Batch Molecular Formula: C45H64N8O10 Batch Molecular Weight: 877.05 Physical Appearance: White lyophilised solid Net Peptide Content: 83% Counter Ion: Trifluoroacetate Solubility: Soluble to 1 mg/ml in water Storage: Desiccate at -20°C Peptide Sequence: 2. ANALYTICAL DATA HPLC: Shows >98% purity Mass Spectrum: Consistent with structure 3. AMINO ACID ANALYSIS DATA Amino Acid Theoretical Actual Amino Acid Theoretical Actual Ala Lys Arg Met Asx Phe Cys Pro 1.00 1.29 Glx Ser Gly Thr 1.00 1.16 His Trp Ile Tyr 1.00 1.00 Leu 1.00 0.89 Val Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use bio-techne.com North America China Europe Middle East Africa Rest of World [email protected] Tel: (800) 343 7475 [email protected] Tel: +44 (0)1235 529449 www.tocris.com/distributors [email protected] Tel: +86 (21) 52380373 Tel:+1 612 379 2956 Print Date: Nov 13th 2018 Product Information www.tocris.com Product Name: Spinorphin Catalog No.: 2931 Batch No.: 1 CAS Number: 137201-62-8 Description: Storage: Desiccate at -20°C Endogenous peptide; inhibits enkephalin-degrading enzymes Solubility & Usage Info: (aminopeptidase, dipeptidyl aminopeptidase III, neprilysin) and angiotensin-converting enzyme. Displays antinociceptive effects Soluble to 1 mg/ml in water in mice. This product is supplied as a lyophilized solid and may be very hard to visualize.
    [Show full text]
  • Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules
    Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules Supervisor: Dr. hab. Elżbieta Kamysz, UG Prof. SUMMARY OF DOCTORAL DISSERTATION “Synthesis and biological studies of endogenous enkephalinase inhibitors and their analogues as potential therapeutic substances in therapy of inflammatory bowel disease and visceral pain” Pharmacological treatment and/or maintenance of remission in inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC) is currently one of the biggest challenges in the field of gastroenterology. The main goal in anti-IBD therapy includes management of inflammation and alleviation of other clinical symptoms like intestinal motility disorder or visceral pain. One of the recent trends in the research of new forms of IBD therapy focuses on the endogenous opioid system. Endogenous opioid peptides such as enkephalins (Met-enkephalin and Leu-enkephalin) participate in the antinociception [1], regulation of gastrointestinal motility [2], regulation of the immune system [3, 4], cardiovascular system [5, 6] anti-inflammatory, hormonal and behavioural responses [7,8]. The action of endogenous opioids in the living organism is strongly regulated by their metabolism and the half-life of enkephalins in the human plasma can be measured within minutes [9], which significantly hampers their pharmacological application. Aminopeptidase N (APN), neutral endopeptidase (NEP), dipeptidyl peptidase III (DPP III) and angiotensin- converting enzyme (ACE) are the major enkephalin-degrading enzymes. These proteases are widely distributed in the human body and are significantly involved in physiological modulation and pathophysiological processes in the gastrointestinal tract [10]. Rat sialorphin (Gln-His-Asn-Pro-Arg), human opiorphin (Gln-Arg-Phe-Ser-Arg) and bovine spinorphine (Leu-Val-Val-Tyr-Pro-Trp-Thr) are endogenous inhibitors of enkephalin-degrading enzymes.
    [Show full text]
  • Custom Peptide Synthesis 2
    Biologically Active Peptides Catalogue 2013-2014 The Companies of the ChinaPeptides Laboratories Group 1 Custom Peptide Synthesis 2 Catalogue Peptides 3 Technical Details 3 Confidentiality, Quoting, Sequence, Counterion, Quantity Purity, Lead time, Cost, Certification of Analysis, Peptide Purity Peptide Content, Additional Analysis, Reconstitution Storage, Shipment, Ordering Prices List for Custom Peptide Synthesis 7 Modification Prices for Custom Peptide Synthesis 8 Contact Addresses 8 Overview of Catalogue Peptides 9 Biologically Functional Peptides 11 Glossary 67 Appendix 69 Sample Certification of Analysis 2 The Companies of the ChinaPeptides Laboratories Group The ChinaPeptides Laboratories Group is a Further information can be obtained from our privately-owned network of companies located web site http://www.chinapeptides.com or by in Zhangjiang High-Tech Park, Shanghai contacting us directly. ChinaPeptides China, specializing in the manufacture of Laboratories is committed to close customer peptides for basic research and for contact. We believe that every project is a therapeutic applications. The companies of partnership and that valuable time and money the Group are specifically equipped to can be saved by discussing the chemistry and complement each other both in terms of scale biology of the project before starting the and focus, allowing ChinaPeptides synthesis. We are dedicated to serving our Laboratories to keep pace with peptide customers. peptide needs and would welcome projects as quantity, synthetic strategy and your input for new products, your comments regulatory requirements change. We can on our products and services, or simply an respond quickly, competently and cost exchange of views on topics related to effectively to customers. needs whether these peptides.
    [Show full text]